<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02901353</url>
  </required_header>
  <id_info>
    <org_study_id>BIO/MOR-I</org_study_id>
    <nct_id>NCT02901353</nct_id>
  </id_info>
  <brief_title>A Prospective, Single-arm, Multi-centre, Observational, Real World Registry</brief_title>
  <acronym>Morpheus</acronym>
  <official_title>A Prospective, Single-arm, Multi-centre, Observational, Real World Registry to Evaluate Safety and Performance of the BioMime™ Morph Sirolimus Eluting Coronary Stent System for Very Long Coronary Lesions.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meril Life Sciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meril Life Sciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single-arm, multi-centre, observational, real world registry to evaluate
      safety and performance of the BioMime™ Morph Sirolimus Eluting Coronary Stent System for very
      long coronary lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title:

      A prospective, single-arm, multi-centre, observational, real world registry to evaluate
      safety and performance of the BioMime™ Morph Sirolimus Eluting Coronary Stent System for very
      long coronary lesions.

      Short Title:

      Morpheus - Global Registry Sponsor: Meril Life Sciences Pvt. Ltd

      Device Used:BioMime™ Morph Sirolimus Eluting Coronary Stent System

      Study population:

      The utilization of the BioMime™ Morph Sirolimus Eluting Coronary Stent System implantation in
      very long (length ≤ 56 mm) coronary lesions in native coronary arteries with reference vessel
      diameter of 2.25 mm to 3.50 mm.

      Enrolment:Minimum 400 patients will be enrolled

      Clinical Sites:Minimum 15 sites

      Objectives:Purpose of this Registry is to evaluate safety and performance of the BioMime™
      Morph Sirolimus Eluting Coronary Stent System in very long (length ≤ 56 mm) coronary lesions
      in native coronary arteries with reference vessel diameter of 2.25 mm to 3.50 mm.

      Study Design:This is a prospective, single-arm, multi-centre, observational, real world
      registry. All patients will be followed for up to 24 months.

      Primary Outcome Measures:Freedom of target lesion failure (TLF) at 6 month and up to 24 month
      TLF is defined as a composite of cardiac death, myocardial infarction and target lesion
      revascularization.

      Secondary Outcome Measures:

        1. MACE at 1, 6, 12 and 24 month Defined as a composite of cardiac death, myocardial
           infarction attributed to the target vessel or Ischemia-driven TLR .

        2. Target vessel failure at 1, 6, 12 and 24 month Defined as cardiac death, myocardial
           infarction attributed to the target vessel, or target vessel revascularization.

        3. Academic Research Consortium (ARC) defined stent thrombosis at 1, 6, 12 and 24 months.

      Definite, probable and possible stent thrombosis during acute, subacute, late and very late
      phase.

      Other Outcome Measures:

        1. Procedure Success:

           It is defined as angiographic evidence of &lt;30% final residual stenosis of the target
           lesion after stent placement and no occurrence of a procedure related MACE prior to
           hospital discharge (for subjects with more than one lesion stented, the worse case is
           counted)

        2. Device Success:

      It is defined as angiographic evidence of &lt;30% final residual stenosis of the target lesion
      using only the assigned device
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Freedom of target lesion failure</measure>
    <time_frame>TLF at 6 month and up to 24 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>1, 6, 12 and 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>1, 6, 12 and 24 month</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Angina Pectoris</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sirolimus Eluting Coronary Stent System</intervention_name>
    <description>Patient with Angina Pectoris will be enrolled for the intervention</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The utilization of the BioMime™ Morph Sirolimus Eluting Coronary Stent System implantation
        in very long (length ≤ 56 mm) coronary lesions in native coronary arteries with reference
        vessel diameter of 2.25 mm to 3.50 mm.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must be at least 18 years of age.

          2. Significant native coronary artery stenosis (&gt; 50% by visual estimate) with lesion
             length of ≤56mm.

          3. The patient or guardian agrees to the protocol requirements and the schedule of
             follow-up and provides informed written consent, as approved by the appropriate
             Institutional Review Board/Ethical Committee of the respective clinical site -

        Exclusion Criteria:

          1. Patients contraindicated to any of the following medications: aspirin, heparin,
             clopidogrel, cobalt-chromium, contrast agents and sirolimus.

          2. An elective surgical procedure is planned that would necessitate interruption of
             antiplatelet drugs during the first 6 months post enrolment.

          3. Patients who are actively participating in another drug or device investigational
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. Bela Merkely, MD, Ph.D, D.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Semmelweis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Szűk Tibor, Ph.D, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Debrecen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. P. Agostoni, Ph.D, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Nieuwegein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Imad A Haddad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jordan Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr. Ramesh Singh, MBBS, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Malaya Medical Centre (UMMC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashok Thakkar, Ph.D</last_name>
    <phone>+91 9879443584</phone>
    <email>ashok.thakkar@merillife.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kartik Vyas, M.Sc.</last_name>
    <phone>+91 9619129010</phone>
    <email>kartik.vyas@merillife.in</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Semmelweis</name>
      <address>
        <city>Budapest</city>
        <state>Europe</state>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. Bela Merkely, MD, Ph.D, D.Sc</last_name>
      <email>Merkely.Bela@kardio.sote.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <state>Europe</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Szűk Tibor, Ph.D, MD</last_name>
      <email>tszuk01@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jordan Hospital</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Imad A Haddad, MD</last_name>
      <email>alhaddad63@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre (UMMC)</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Selangor</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Ramesh Singh, MBBS, MRCP</last_name>
      <email>ramesh@ummc.edu.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Germany</state>
        <zip>3435CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. P. Agostoni</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Jordan</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

